Current Report Filing (8-k)
22 Mai 2019 - 10:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
May 22, 2019
Date of report (Date of earliest event reported)
_______________________
Valeritas Holdings, Inc.
(Exact name of registrant as specified in its charter)
________________________
|
|
|
|
|
Delaware
|
001-38038
|
46-5648907
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
750 Route 202, Suite 600
Bridgewater, NJ
(Address of principal executive offices)
|
08807
(Zip Code)
|
|
Registrant's telephone number, including area code
(908) 927-9920
(Former name or former address, if changed since last report)
________________________
|
Check the appropriate box below if the Form 8‑K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
☐
|
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12).
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b)).
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per value
|
VLRX
|
The Nasdaq Capital Market
|
Item 8.01. Other Events.
On May 22, 2019, Valeritas Holdings, Inc. issued a press release announcing that it presented additional results from its VERDICT study at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting.
The full text of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
|
|
|
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Valeritas Holdings, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
Dated: May 22, 2019
|
|
|
By:
s/ John E. Timberlake
|
|
|
|
|
Name: John E. Timberlake
|
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
Valeritas (NASDAQ:VLRX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Valeritas (NASDAQ:VLRX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about Valeritas Holdings Inc (NASDAQ): 0 recent articles
Plus d'articles sur Valeritas Holdings Inc.